



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling
Cabinet Secretary

Pharmaceutical and Therapeutics Committee
November 18th, 2015

Location: 1 Davis Square, Conference Room 93
Time: 2:00 AM – 2:30 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Committee Members Present:

Robert Stanton, Pharm.D., Chair
Bradley Henry, M.D., Vice Chair
Elizabeth Baldwin, RN, MSN, PNP, APRN-BC
Scott Brown, R.Ph.
Kenneth Hilsbos, M.D.
Steve Neal, Pharm.D.
Tom Kines, R.Ph.

Absent:

Adam Breinig, D.O.
Hazi Nazha, M.D.
Chris Terpening, Pharm.D., PhD.

Division of Medicaid Staff Present:

Vicki Cunningham, R.Ph.
Brian Thompson, Pharm.D., MS
Bill Hopkins
Doug Sorvig

Contract Staff Present:

Goold Health Systems:
Laureen Biczak, DO

Other Contract / State Staff Present:

None

I. Call to Order

Robert Stanton, Pharm.D., Chair, called the meeting to order at 2:14pm.

II. Welcome and Introductions

Vicki Cunningham welcomed all present in person and by phone to the Committee meeting. Committee members, BMS staff, and Goold staff introduced themselves. All Committee members attended by phone.

III. Administrative Items / Updates

A. Reason for Emergency P & T Committee meeting

Vicki Cunningham explained to the Committee the reason for the emergency meeting. Specifically, she explained that Sanofi recently recalled all Auvi-Q epinephrine auto-injectors and removed all of the product from the market. The company has not been able to provide a time frame as to when the product will be available again. Since West Virginia Medicaid has had Auvi-Q as the sole preferred product since 7/1/2015, the meeting was necessary for the Committee to consider a new preferred product in this category.

IV. Drug Class Announcements

Only the Epinephrine class was reviewed. There were no other drug class announcements.

V. Public Comments

There were no public comments.

VI. Executive Session

There was no executive session.

VII. Therapeutic Category Reviews/Committee Recommendations

A. Epinephrine, Self-Injected

Vicki Cunningham explained that EpiPen is an alternative branded agent in this category for which there is a supplemental rebate available. A generic product is also currently preferred. The recommendation is to move EpiPen to preferred status and move Auvi-Q to non-preferred status for the remainder of calendar year 2015 and for 2016.

A motion was made by Scott Brown and seconded by Dr. Henry to change the PDL category as recommended. A brief discussion followed. Scott Brown asked if it would be possible to reconsider the category if and when Auvi-Q becomes available again. Vicki Cunningham

explained that all current contracts allow termination with proper notice and that if a product becomes available in the category, it is possible to reconsider it. A vote was held. All members were in favor and the motion was approved. The category is now as listed below.

EPINEPHRINE, SELF-INJECTED	
epinephrine EPIPEN (epinephrine)	ADRENACLICK (epinephrine) AUVI-Q (epinephrine)

VIII. Next Meeting

The next P&T Committee Meeting is scheduled for January 27th, 2016, 2-5 PM, Diamond Building

IX. Other Business

No other business was presented.

X. Adjournment

The Committee adjourned the meeting at 2:19pm